Crossbred Feline/cat — FDA Adverse Event Profile

Crossbred Feline/cat Pet Health Insights

Across the FDA Center for Veterinary Medicine adverse event database, Crossbred Feline/cat accounts for 548 submitted reports and currently ranks #134 by report volume within the cat population. Of those reports, 35 involved a death outcome — a 640.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 6.7 years, with an average recorded body weight of 5.0 kg (11.0 lbs). These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.

The most frequently reported clinical signs for Crossbred Feline/cat are Lack of efficacy (ectoparasite) - flea (89 reports), Lethargy (see also Central nervous system depression in 'Neurological') (59 reports), Application site hair loss (55 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Fluralaner Spot-On Solution appears in 185 reports and is the single most-referenced drug, followed by Nitenpyram (64) and Fluralaner/Moxidectin Spot-On (48). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same cat species.

Outcome coding on the 549 reports with a recorded status is dominated by Ongoing (41.2% of coded outcomes). Annual submission volume ranges from 2,010 to 2,025 reports across the 16 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual cat.